Trial
NCT03773172
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
MedImmune LLC; AstraZeneca
Condition
Cardiovascular Diseases
Intervention
MEDI6012
Why stopped
Early termination due to COVID-19
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-12